Last reviewed · How we verify
Intraduodenal quinine hydrochloride
Intraduodenal quinine hydrochloride is a Bitter taste receptor agonist Small molecule drug developed by Universitaire Ziekenhuizen KU Leuven. It is currently FDA-approved for Type 2 diabetes mellitus. Also known as: ID QHCl.
Intraduodenal quinine hydrochloride acts as a bitter taste receptor agonist that stimulates local sensory pathways in the small intestine to modulate glucose homeostasis and metabolic function.
Intraduodenal quinine hydrochloride acts as a bitter taste receptor agonist that stimulates local sensory pathways in the small intestine to modulate glucose homeostasis and metabolic function. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Intraduodenal quinine hydrochloride |
|---|---|
| Also known as | ID QHCl |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Drug class | Bitter taste receptor agonist |
| Target | TAS2R (bitter taste receptors) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Quinine activates bitter taste receptors (TAS2Rs) located on enteroendocrine cells in the duodenum, triggering the release of incretin hormones and other metabolic regulators. This localized intestinal stimulation enhances glucose-dependent insulin secretion and improves postprandial glucose control without systemic absorption of the drug.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal distress
- Nausea
- Bitter taste sensation
Key clinical trials
- IG vs ID Bitter Administration (PHASE4)
- The Effect of Bitter Taste Receptor Agonists on The Gastrointestinal Tract, Hunger and Food Intake (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intraduodenal quinine hydrochloride CI brief — competitive landscape report
- Intraduodenal quinine hydrochloride updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI
Frequently asked questions about Intraduodenal quinine hydrochloride
What is Intraduodenal quinine hydrochloride?
How does Intraduodenal quinine hydrochloride work?
What is Intraduodenal quinine hydrochloride used for?
Who makes Intraduodenal quinine hydrochloride?
Is Intraduodenal quinine hydrochloride also known as anything else?
What drug class is Intraduodenal quinine hydrochloride in?
What development phase is Intraduodenal quinine hydrochloride in?
What are the side effects of Intraduodenal quinine hydrochloride?
What does Intraduodenal quinine hydrochloride target?
Related
- Drug class: All Bitter taste receptor agonist drugs
- Target: All drugs targeting TAS2R (bitter taste receptors)
- Manufacturer: Universitaire Ziekenhuizen KU Leuven — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: ID QHCl
- Compare: Intraduodenal quinine hydrochloride vs similar drugs
- Pricing: Intraduodenal quinine hydrochloride cost, discount & access